Regeneron Pharmaceuticals reported better-than-expected second-quarter earnings but experienced setbacks with multiple FDA regulatory actions. The FDA issued complete response letters for odronextamab, Regeneron's bispecific antibody for lymphoma, and delayed approvals for high-dose Eylea applications due to manufacturing issues at a Catalent facility. The company anticipates resolving these manufacturing challenges to secure favorable FDA decisions.